- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01589705
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
July 29, 2012 updated by: Ismail Kocyigit, TC Erciyes University
Endothelial Dysfunction in Patients With Polycystic Kidney Disease
There are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with Autosomal dominant polycystic kidney disease (ADPKD), the association between serum uric acid level and endothelial dysfunction has not been elucidated yet in these patients.
Therefore, in this study, the investigators aimed to examine the relationship between the uric acid level and the ED in normotensive ADPKD patients with preserved renal function.
Study Overview
Status
Terminated
Conditions
Detailed Description
This is the first study to evaluate the relationship between uric acid and endothelial dysfunction in patients with early stage ADPKD
Study Type
Observational
Enrollment (Actual)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kayseri, Turkey, 38039
- Erciyes University Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with early stage(preserved renal function) Autosomal dominant polycystic kidney disease (n = 91) from two academic medical center.We also excluded the patients with a previous diagnosis of hypertension, gout, diabetes, current use of oral antidiabetic medication, insulin, thiazide, allopurinol or uricosuric, or a fasting glucose level 126 mg/dl.
In addition, the subjects with a history of smoking or current use of any anti-hypertensive medication and statins were excluded
Description
Inclusion Criteria:
- ADPKD patients with normal renal function,
- Normotensive ADPKD patients
Exclusion Criteria:
- Patients with impaired kidney function,
- Atherosclerotic disorders,
- Diagnosis of hypertension, gout, diabetes,
- Using of insulin, thiazide, allopurinol or uricosuric drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
polycystic kidney ,no hypertension
The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of asymmetric dimethylarginine (ADMA) and flow mediated dilatation (FMD)
Time Frame: 4 months
|
ADMA,FMD and uric acid measurements were performed to determine endothelial dysfunction in ADPKD patients
|
4 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Bulent Tokgoz, Professor, Erciyes University Medical School
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
April 1, 2012
Study Completion (Actual)
April 1, 2012
Study Registration Dates
First Submitted
April 30, 2012
First Submitted That Met QC Criteria
May 1, 2012
First Posted (Estimate)
May 2, 2012
Study Record Updates
Last Update Posted (Estimate)
July 31, 2012
Last Update Submitted That Met QC Criteria
July 29, 2012
Last Verified
July 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Erciyes 2011/273
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Kidney, Autosomal Dominant
-
Emory UniversityPKD FoundationCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Mario Negri Institute for Pharmacological ResearchOtsuka Pharmaceutical Italy S.r.l.CompletedAutosomal Dominant Polycystic Kidney DiseaseItaly
-
Mayo ClinicUniversity of Kansas Medical CenterCompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
CHU de ReimsCompletedAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Regional Hospital HolstebroAarhus University HospitalCompletedAutosomal Dominant Polycystic Kidney DiseaseDenmark
-
University Hospital, BrestUnknownAutosomal Dominant Polycystic Kidney DiseaseFrance
-
Federico II UniversityCompletedAutosomal Dominant Polycystic Kidney Disease
-
Kadmon Corporation, LLCTerminatedAutosomal Dominant Polycystic Kidney Disease (ADPKD)United States